Related Experiment Video
Updated: May 5, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Apical hypertrophic cardiomyopathy in association with pulmonary artery hypertension
Mehdi Peighambari1, Mozghan Parsaei, Anita Sadeghpour
1Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Apical Hypertrophic Cardiomyopathy (HCM) is rare. This study reports two cases of apical HCM associated with significant pulmonary artery hypertension, with no other identifiable cause.
Area of Science:
- Cardiology
- Pulmonology
Background:
- Apical Hypertrophic Cardiomyopathy (HCM) is a distinct subtype of HCM, accounting for 1%-2% of all HCM diagnoses.
- HCM is characterized by unexplained left ventricular hypertrophy.
Observation:
- Two patients presented with apical HCM.
- Both patients exhibited significant pulmonary artery hypertension.
- No other underlying conditions were identified as a cause for the pulmonary hypertension.
Findings:
- Echocardiography, cardiac catheterization, and pulmonary function tests were performed.
- The findings suggest a potential association between apical HCM and unexplained pulmonary artery hypertension.
Implications:
- This association may warrant further investigation into the pathophysiology linking apical HCM and pulmonary hypertension.
- Understanding this relationship could lead to improved diagnostic and therapeutic strategies for patients with these co-occurring conditions.
Abstract:
Apical Hypertrophic Cardiomyopathy is an uncommon condition constituting 1% -2% of the cases with Hypertrophic Cardiomyopathy (HCM) diagnosis. We interestingly report two patients with apical hypertrophic cardiomyopathy in association with significant pulmonary artery hypertension without any other underlying reason for pulmonary hypertension. The patients were assessed by echocardiography, cardiac catheterization and pulmonary function parameters study.
More Related Videos
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy V: Interprofessional Care